Tolerx

company

About

Tolerx develops novel therapies that modulate T-cell activities to treat patients with autoimmune diseases, diabetes and cancer.

  • 51 - 100

Details

Last Funding Type
Series D
Last Funding Money Raised
$61M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2000
Number Of Employee
51 - 100
Operating Status
Active

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$92M
Tolerx has raised a total of $92M in funding over 2 rounds. Their latest funding was raised on Oct 21, 2006 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 21, 2006 Series D $61M 1 Bear Stearns Health Innoventures L.P Detail
Mar 29, 2005 Series D $31M 1 Bear Stearns Health Innoventures L.P Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Tolerx is funded by 1 investors. Bear Stearns Health Innoventures L.P are the most recent investors.
Investor Name Lead Investor Funding Round
Bear Stearns Health Innoventures L.P Yes Series D